TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Executive Summary

• TempraMed Technologies Ltd. closed a fully‑subscribed non‑brokered private placement of 3,322,153 units at $0.76 per unit, raising CAD $2,524,836.28 in gross proceeds.
• The offering included common shares and share purchase warrants (exercise price $1.00, exercisable until July 12 2027). Finder’s fees of $146,536.15 were paid, and additional finder‑related shares and warrants were issued.
• At the Annual General Meeting, shareholders re‑elected five directors, added a new director (Ran Enoch), approved MNP LLP as auditors, and adopted an Equity Incentive Plan authorizing up to 14,687,069 equity awards.

Key Details

• Units Issued: 3,322,153 units @ $0.76 each → CAD $2,524,836.28 gross proceeds.
• Unit Composition: 1 common share + 1 share purchase warrant per unit.
• Warrant Terms: Exercise price $1.00 per share; exercisable until July 12 2027.
• Finder Compensation: Cash fees of $146,536.15; issuance of 189,307 finder shares and 1,500 finder warrants (same exercise terms).
• Statutory Hold Period: All securities subject to hold expiring May 12 2026.
• Use of Proceeds: Working capital and inventory buildup to meet growing distribution demand.
• AGM Results: Re‑election of Ilan Cohen, Ron Nagar, Nancy Goertzen, John Sinclair, Julia Becker; addition of Ran Enoch as director.
• Auditor Appointment: MNP LLP approved as the Company’s auditors.
• Equity Incentive Plan Adoption: Authorization for up to 14,687,069 stock options, RSUs, deferred share units, and performance share units, pending regulatory approvals.

Notable Quotes

“Closing of this high‑demand, equity financing with strong institutional participation is a powerful validation of TempraMed's strategy, technology, and momentum,” – Ron Nagar, CEO.